Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)

被引：0

作者：

Cavo, Michele ^{[1
]}

Corradini, Paolo ^{[2
]}

Di Raimondo, Francesco ^{[3
]}

Petrini, Mario ^{[4
]}

Cafro, Anna Maria ^{[5
]}

di Toritto, Tommaso Caravita ^{[6
]}

Offidani, Massimo ^{[7
]}

Semenzato, Gianpietro ^{[8
]}

Zambello, Renato ^{[9
]}

Lazzaro, Antonio ^{[10
,11
]}

Petrucci, Maria Teresa ^{[12
]}

Rodeghiero, Francesco ^{[13
]}

Simcock, Mathew ^{[14
]}

Slaughter, Ana ^{[14
]}

Herring, Jennifer ^{[15
]}

Peluso, Teresa ^{[14
]}

Palumbo, Antonio ^{[16
]}

机构：

[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy

[3] Univ Catania, Dept Clin & Mol Biomed, Catania, Italy

[4] Univ Pisa, Hematol, Pisa, Italy

[5] Osped Niguarda Ca Granda, Milan, Italy

[6] S Eugenio Hosp, Div Hematol, Rome, Italy

[7] Osped Riuniti Ancona, Haematol Clin, Ancona, Italy

[8] Venetian Inst Mol Med, Padua, Italy

[9] Univ Padua, Sch Med, Hematol & Clin Immunol Sect, Dept Med, Padua, Italy

[10] Hosp Piacenza, Hematol Unit, Piacenza, Italy

[11] Hosp Piacenza, Bone Marrow Transplant Ctr, Piacenza, Italy

[12] Univ Roma La Sapienza, Dept Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy

[13] S Bortolo Hosp, Dept Cell Therapy & Hematol, Vicenza, Italy

[14] Celgene Int Sarl, Boudry, Switzerland

[15] Celgene Corp, Summit, NJ USA

[16] Univ Turin, Turin, Italy

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Palumbo, Antonio
Corradini, Paolo
Cavo, Michele
Delforge, Michel
Weisel, Katja C.
Ocio, Enrique M.
Di Raimondo, Francesco
Hansson, Markus
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Peluso, Teresa
Sternas, Lars
Zaki, Mohamed H.
Moreau, Philippe
BLOOD, 2015, 126 (23)
[2] The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in refractory or relapsed and refractory multiple myeloma
Dimopoulos, Meletios A.
Weisel, Katja C.
Cavo, Michele
Corradini, Paolo
Delforge, Michel
Morgan, Gareth J.
Hansson, Markus
Palumbo, Antonlo
Oclo, Enrique M.
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Leupin, Nicolas
Nikolova, Zariana G.
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] THE STRATUS TRIAL (MM-010): ANALYSIS OF THE ITALIAN SUBGROUP OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE
Cavo, M.
Corradini, P.
Di Raimondo, F.
Vacca, A.
Petrini, M.
Cafro, A. M.
di Toritto, T. Caravita
Offidani, M.
Semenzato, G.
Zambello, R.
Lazzaro, A.
Patriarca, F.
Petrucci, M. T.
Rodeghiero, F.
Simcock, M.
Slaughter, A.
Herring, J.
Peluso, T.
Palumbo, A.
HAEMATOLOGICA, 2016, 101 : 795 - 795
[4] Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Moreau, Philippe
Palumbo, Antonio
Corradini, Paolo
Cavo, Michele
Delforge, Michel
Weisel, Katja C.
Ocio, Enrique M.
Cafro, Annamaria
Rollig, Christoph
Knop, Stefan
de Arriba, Felipe
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Watkins, Latisha
Herring, Jennifer
Biyukov, Tsvetan
Peluso, Teresa
Zaki, Mohamed H.
Dimopoulos, Meletios A.
BLOOD, 2015, 126 (23)
[5] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
Schey, Steve
Dhanasiri, Sujith
Lee, Dawn
Sternas, Lars
Yu, Xin
Zaki, Mohamed H.
Elvidge, Jamie
O'Dwyer, Michael
BLOOD, 2014, 124 (21)
[6] Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Hudgens, Stacie
Yu, Zhinuan
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Dimopoulos, Meletios A.
Palumbo, Antonio
Corradini, Paolo
Cavo, Michele
Delforge, Michel
Di Raimondo, Francesco
Weisel, Katja C.
Oriol, Albert
Hansson, Markus
Vacca, Angelo
Jesus Blanchard, Maria
Goldschmidt, Hartmut
Doyen, Chantal
Kaiser, Martin
Petrini, Mario
Anttila, Pekka
Cafro, Anna Maria
Raymakers, Reinier
San-Miguel, Jesus
de Arriba, Felipe
Knop, Stefan
Roellig, Christoph
Ocio, Enrique M.
Morgan, Gareth
Miller, Neil
Simcock, Mathew
Peluso, Teresa
Herring, Jennifer
Sternas, Lars
Zaki, Mohamed H.
Moreau, Philippe
BLOOD, 2016, 128 (04) : 497 - 503
[8] Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in the MM-003 trial.
Weisel, Katja
Moreau, Philippe
Gibson, Craig J.
Song, Kevin W.
Saunders, Owain
Sternas, Lars Axel
Hong, Kevin
Zaki, Mohamed H.
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI)
Matous, Jeffrey
Siegel, David Samuel DiCapua
Duong, Hien Kim
Kasserra, Claudia
Sternas, Lars
Jacques, Christian
Klesczewski, Kenneth
Zaki, Mohamed H.
Shah, Jatin J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[10] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003
Goldschmidt, Hartmut
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →